Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001390390 | SCV001592109 | pathogenic | Familial aplasia of the vermis; Meckel-Gruber syndrome; Nephronophthisis | 2023-12-06 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys2447Asnfs*10) in the CEP290 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 33 amino acid(s) of the CEP290 protein. This variant is present in population databases (rs745589877, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with CEP290-related conditions. ClinVar contains an entry for this variant (Variation ID: 1076473). This variant disrupts a region of the CEP290 protein in which other variant(s) (p.Leu2448Thrfs*8) have been determined to be pathogenic (PMID: 16682973, 16909394, 29588463). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002488212 | SCV002786935 | pathogenic | Leber congenital amaurosis 10; Meckel syndrome, type 4; Senior-Loken syndrome 6; Joubert syndrome 5; Bardet-Biedl syndrome 14 | 2022-04-15 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003136065 | SCV003826169 | likely pathogenic | not provided | 2021-11-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003469771 | SCV004216653 | likely pathogenic | Bardet-Biedl syndrome 14 | 2023-04-26 | criteria provided, single submitter | clinical testing |